Gain Therapeutics SA Announces Closing of EU 2.5 Million Series A Financing to Develop Novel Brain-Penetrant Non-Competitive Pharmacological Chaperones for Rare Lysosomal Storage Diseases and CNS Indications
GT Gain Therapeutics SA today announces that it has closed a €2.5 Million series A financing with VitaTech S.A. (€1.1Mio), Helsinn Investment Fund S.A. (€1Mio), and with existing investor TiVenture S.A. (€0.4).
Gain Therapeutics SA is a private company, based in Lugano (Switzerland) and with a branch in Barcelona, that exclusively licensed an advanced computational technology (Site-directed Enzyme Enhancement Therapy, SEE-Tx®) used to identify next generation brain-penetrant non-competitive pharmacological chaperones. SEE-Tx® applicable to all diseases with a known genetic mutation in target proteins, allows the identification of brain-penetrant small molecules that provide a gain-of-function of misfolded proteins. Gain Therapeutics has already identified molecules for the treatment of a group of metabolic disorders called lysosomal storage disorders and some chronic degenerative diseases of the nervous system.
Prof. Xavier Barril (CSO) commented: “The closing of this first part of series A funding will allow us to further support the development of our most advanced programs and namely GM1 Gangliosidosis, Gaucher Disease and GBA-related Parkinson Disease. And as such will accelerate the identification of clinical candidates to be tested in first-of-human studies.”
Dr. Lorenzo Leoni (CEO, Co-Founder, Managing Partner of TiVenture) added: “VitaTech, Helsinn Investment Fund and TiVenture will also bring drug development, pharmaceutical development, global licensing and partnering expertise that will contribute to bringing customized solutions to patients, where high unmet medical needs are still very much present across the globe”.
Riccardo Braglia (Helsinn Group Vice Chairman), commented: “Gain Therapeutics, with a flexible and powerful platform technology, offers huge potential to identify orally available therapies for lysosomal storage and CNS disorders. It fits perfectly in the portfolio companies with state-of-the-art technologies of the Helsinn Investment Fund”.
Roberto Barzi (Director VitaTech) added: “We are delighted for the closing of our first investment in Gain Therapeutics that, with a powerful computation modeling technology supporting a traditional drug discovery approach, fits perfectly within our strategy to invest in companies positioned at the convergence of Healthcare and Technology”.
About Gain Therapeutics SA
Gain Therapeutics is a preclinical stage biotech company developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx® technology. The company has several discovery programs in lysosomal storage diseases and CNS indications at various stages of development, all of which validate the platform and offer significant partnering opportunities. Gain Therapeutics was established in 2017 in Lugano by experienced biotech and pharma entrepreneurs. It was initially financed by TiVenture.
For more information: www.gaintherapeutics.com
About TiVenture SA
TiVenture is a seed investment fund owned by the Fondazione Centenario Banca Stato (Switzerland) that invests in early stage companies with innovative technologies and high growth potential, principally in southern Switzerland. TiVenture is actively looking and ready to support exceptional founders and entrepreneurs developing scalable products for the global market. TiVenture has a diversified portfolio of companies and is mainly active in the life science, medical, high-tech and IT sectors.
For more information, visit www.tiventure.ch
About Helsinn Investment Fund S.A., SICAR
The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients.
Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions.
For more information, visit www.helsinninvestmentfund.com
About VitaTech SA
VitaTech invests in European early stage and growth-phase high-tech companies positioned at the convergence of healthcare and technology. VitaTech is funded by the Zambon Family and by other European ultra-high-net-worth private investors and family offices.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190218005150/en/
Contact information
Gain Therapeutics SA
Manolo Bellotto, PhD
General Manager
+41-91-921-1524
mbellotto@gaintherapeutics.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dave & Buster’s International Cements Its Presence in the APAC Region16.4.2024 15:00:00 CEST | Press release
Dave & Buster's Entertainment, Inc., the ultimate destination for food, drink and entertainment is delighted to announce its latest franchise agreement furthering the brands development in APAC. Dave & Buster’s has finalized a deal to open five new stores in the Philippines, raising the international development store count to 38. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416173901/en/ Antonio Bautista, Chief International Development Officer of Dave & Buster’s and Paul Manuud, President of The Bistro Group (Photo: Business Wire) Antonio Bautista, Chief International Development Officer at Dave & Buster’s, stated "We are thrilled to announce our expansion into the Philippines, marking another significant milestone in our global growth strategy. Our partnership with The Bistro Group in the Philippines aligns with our mission to deliver exceptional 'Eat, Drink, Play, and Watch' experiences to a broader audience. The Bi
Experian Named a Leader in IDC MarketScape: Worldwide Enterprise Fraud Solutions 2024 Vendor Assessment16.4.2024 15:00:00 CEST | Press release
Experian announced that the company was named a Leader in the IDC MarketScape: Worldwide Enterprise Fraud Solutions 2024 Vendor Assessment (doc #US51939124, March 2024). The report evaluates each vendor’s advanced fraud detection capabilities, alignment with customer needs, and future strategy and roadmap for innovation. Experian offers an integrated digital identity and fraud risk platform that delivers analytics-driven outcomes through sophisticated orchestration. The IDC MarketScape report noted, “In addition to evaluating the transactional data for potential fraud, Experian's CrossCore solution includes identity-authentication tools. The solution uses identity data, device intelligence, email and phone intelligence, alternative identity data, biometrics, behavioral biometrics, one-time passwords, and document verification to confirm identities and aid with identity protection, including synthetic identity protection. Experian utilizes multiple data partnerships in its fraud solutio
Laserfiche Reimagines Partner Ecosystem to Empower Solution Providers Worldwide16.4.2024 15:00:00 CEST | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — has announced a number of channel momentum milestones as the organization marks the start of a new era of growth and technology innovation. In 2024, the company is strengthening its partner ecosystem to deliver more ways for organizations to transform the way they manage content, automate workflows and accelerate how business gets done. “We’ve seen incredible progress across all areas of Laserfiche over the past year, including growth into emerging industries and regions, increased investment into our channel program and resources, and hiring of key leaders,” said Laserfiche CEO Karl Chan. “In 2024, we look forward to building on this momentum, continuing to strengthen our partner ecosystem and bringing even more solutions to market that empower organizations and inspire the world.” Expanding Global Footprint Over the past year, Laserfiche saw widespread adoption of digital transf
Merck Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety Testing16.4.2024 14:00:00 CEST | Press release
Merck, a leading science and technology company, has launched the first all-in-one, validated genetic stability assay of its kind. The Aptegra™ CHO genetic stability assay leverages whole genome sequencing and bioinformatics to significantly accelerate biosafety testing for clients and therefore, their move into commercial production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416870388/en/ A scientist preparing samples in the next-generation sequencing laboratory at Merck’s Rockville, Maryland, USA site. (Photo: Business Wire) “Driving innovation in biosafety testing is essential to bringing new therapies to patients faster,” said Benjamin Hein, Head of Life Science Services, Life Science business of Merck. “CHO genetic stability testing has remained relatively unchanged for many years. The Aptegra™ platform transforms biosafety testing with a digital solution using next-generation sequencing.” Currently, FDA guidanc
XYZ Reality Welcomes Data Center Industry Leaders Christian Belady and Brian Mattson as Strategic Advisors16.4.2024 14:00:00 CEST | Press release
XYZ Reality, the leading engineering grade augmented reality (AR) platform for data center and mission critical construction, is proud to announce the appointment of data center industry veterans Christian Belady and Brian Mattson as Strategic Advisors. With their extensive experience and innovative vision, they will help guide XYZ Reality in enhancing its data center construction solution and product roadmap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416398782/en/ Christian Belady (Photo: Business Wire) Christian Belady, recognized as one of the "5 People who changed the data center" industry, brings a wealth of expertise in managing data center and infrastructure development at a global scale. Formerly Vice President and Distinguished Engineer at Microsoft, Belady developed one of the largest data center footprints in the world. Notably, during his tenure at Hewlett Packard, he was the innovator behind the Power Us